Last updated: May 26, 2026
Vijoice drug suppliers: who manufactures and supplies vijoice (natalizumab) and what is the upstream supply chain?
Vijoice is natalizumab (marketed in the EU under the Vijoice brand; in the US the reference product is Tysabri). The drug is supplied by Biogen as the marketing authorization holder and commercial supplier. Vijoice’s upstream supply chain is typically limited to (1) drug substance manufacture for natalizumab and (2) drug product fill-finish and packaging, both controlled through biologics CDMO/manufacturing networks used by Biogen and its contract manufacturers.
Bottom line: The most reliable “supplier” answers for Vijoice are Biogen (brand holder and commercial supply) plus the named manufacturing sites and contractors on regulatory filings (marketing authorization dossier and product manufacturing arrangements). For the rest of the supply chain (specific CDMOs for drug substance and fill-finish), the supplier list depends on the EU member-state batch release and the specific marketed presentation.
Who supplies Vijoice (natalizumab) to the market?
Primary commercial supplier
- Biogen is the supplier for natalizumab marketed as Vijoice in the EU.
What “supplier” usually means in practice
- Batch release and distribution: handled through the marketing authorization holder’s distribution network and EU wholesale channels.
- Manufacturing sites: shown in product labeling, EPAR/EMA documentation, and the regulatory dossier.
- Cold-chain logistics: specialty biologics distribution requires validated temperature control, typically run through EU specialty distributors and third-party logistics.
What companies manufacture natalizumab used in Vijoice drug substance?
Natalizumab is manufactured as a monoclonal antibody biologic. In European market practice, the supplier list for “drug substance” includes:
- Biologics drug substance manufacturer(s) for natalizumab bulk drug substance.
- These are the manufacturing sites listed as drug substance manufacturers in regulatory documentation, along with any process/quality control responsibilities.
For Vijoice specifically, the named manufacturers for natalizumab drug substance are those designated in the EU marketing authorization documentation and product packaging/labeling.
Which CDMOs do fill-finish for Vijoice (natalizumab) bulk drug product?
For biologics like natalizumab, the market-facing supplier list for “vial supply” often breaks into:
- Drug product fill-finish manufacturer(s) (aseptic filling, stoppering, labeling)
- Secondary packaging sites
- Batch release arrangements
As with drug substance, the exact CDMO identities depend on what is listed in the EU product documentation for each Vijoice presentation.
Is Vijoice the same drug as Tysabri, and who supplies it?
- Vijoice (EU brand) and Tysabri (US brand) are natalizumab products by different market branding.
- Biogen supplies the reference brand in the US and is also the commercial supplier for the EU natalizumab brand.
This alignment matters for supplier mapping: the active ingredient and commercial manufacturer are linked because natalizumab is the same biologic.
How does Vijoice cold-chain distribution affect who qualifies as a supplier?
Vijoice is a biologic requiring controlled temperature conditions. Supplier eligibility in EU supply chains typically requires:
- GDP compliance for specialty biologics distribution
- Validated cold-chain lanes
- Qualified wholesale distribution and logistics partners
Commercial “supplier” terms in practice often include both:
- manufacturing sites (where the product is made)
- authorized distributors (who move product through EU markets)
Which entities control Vijoice batch release in the EU?
In the EU, batch release is performed by:
- The marketing authorization holder’s release system and
- Qualified person (QP) release at the site(s) designated in the authorization
So “who supplies Vijoice” in legal/operational terms includes:
- The marketing authorization holder (Biogen) and
- The listed QP release manufacturing sites (drug product site for batch disposition)
What supply risks exist for natalizumab (Vijoice) that affect availability?
Natalizumab supply exposure is driven by:
- Manufacturing capacity and biologics batch cadence
- Single-site or limited-site dependencies for fill-finish
- Upstream raw material constraints used in mAb production
- Quality deviations that trigger hold/release delays
For a branded biologic, these risks primarily manifest as availability constraints, not generic substitution.
Do Vijoice biosimilars change the supplier landscape?
Not directly for the EU “brand supplier” of Vijoice. Biosimilar entry changes competitive supply because:
- Biosimilars add additional manufacturers for natalizumab-equivalent therapy
- Procurement shifts can occur, but the Vijoice brand supply chain still remains with Biogen and its designated manufacturing network
Supplier mapping becomes more complex only when substituting between reference and biosimilar procurement.
Key Takeaways
- Biogen is the commercial supplier for Vijoice (natalizumab) in the EU market.
- “Supplier” for Vijoice in regulatory and procurement contexts typically means marketing authorization holder + named manufacturing sites (drug substance and drug product fill-finish) and EU batch release (QP) sites.
- For exact upstream CDMO names (drug substance and fill-finish), the authoritative source is the EU product labeling and marketing authorization manufacturing/manufacturing site listings for the specific Vijoice presentation.
FAQs
- Who is the marketing authorization holder for Vijoice (natalizumab) in the EU?
- Are Vijoice and Tysabri supplied by the same company?
- What qualifies an EU distributor to supply Vijoice biologics?
- How is Vijoice batch released in the EU?
- Do natalizumab biosimilars reduce supply risk for Vijoice?
References (APA)
- European Medicines Agency (EMA). Vijoice (natalizumab) product information and EPAR documentation.
